COPD: From the stethoscope to the spirometer

Letter to the editor:

In the world, about 3 billion of people, predominantly women, young girls and small children, are exposed to household air pollution, secondary to indoor cooking with biomass and coal.1 Because the combustion of solid fuels produces a mixture of air pollutants, from respirable particles to gases, this exposure is associated with chronic obstructive pulmonary disease (COPD), and this association is well documented.2 During their lifetime, some women can be exposed to biomass smoke for 30–40 years, or 60,000 h of exposure.3 This can be the biggest risk factor for COPD in the world, even predominates in developing countries.4 In rural areas, 90% of households continue to use this highly polluting biomass fuel. In 2008, in the Portuguese region of Lisbon, the BOLD study showed a GOLD stage 1 or higher COPD prevalence of 9.2% in never-smokers.5

Despite the fact that, within never-smokers, COPD has been neglected and excluded in the majority of large studies,6 the association observed between the exposure to biomass smoke and COPD is as great as the risk of active smoking. The prevalence of COPD among never-smokers varies widely across the countries, but at least one fourth of patients with COPD are never-smokers. Many are women, in whom this disease is understudied.7 But cooking with biomass and coal, rather than a recent phenomenon, is an old problem, still persisting in rural areas of many developed countries, as in Portugal, Spain, Canada, Australia or US. Thereby, we wonder why COPD is a disease only recently concern, and usually associated with tobacco epidemic.

In fact, the recognition of emphysema and chronic bronchitis, and the evolution of their knowledge, cover nearly four centuries, since the Bonets’s description of ‘‘voluminous lungs’’, in 1679.8 In 1821, Laennec, the inventor of the stethoscope, describes the emphysema as a disease that was ‘‘very little known’’ and ‘‘completely overlooked’’.8 However, since the discovery and use of the stethoscope, he wrote, he believed to be a much more common problem. With Laennec begins the modern era of COPD. In that time smoking was rare, but urban atmospheric pollution, in particular coal smoke, and domestic pollution from open fireplaces, in houses with poor ventilation, was a well-known phenomena, as was the conditions of work in cotton factories. In 1868, Manchester’s first Medical Officer of Health said that the normal condition of the working man of middle age in Manchester was bronchitic.9 Occupation, domestic pollution and atmospheric pollution were, in the 19th century, well known risk factors for chronic bronchitis and emphysema.

Until recently, the diagnosis of emphysema and chronic bronchitis was based on symptoms of dyspnea, cough and expectoration, and on physical examination of an enlarged chest. The diagnosis of emphysema, according to Ronald Christie, in 1944, should be considered certain in the presence of dyspnea on exertion and of insidious onset, not due to bronchospasm or left ventricular failure, in a patient with physical signs of emphysema. But by the time clinical signs are present, COPD is in a moderate or advanced stage,10 and we miss not only the early diagnosis but most diagnosis. Furthermore, before the CIBA Guest Symposium,

Conflicts of interest

The authors have no conflicts of interest to declare.

References

10. Díaz-Lobato J.M., Alonso J.M., Carratalá, S. Mayoralas Hospital Ramón y Cajal, Neumología, Carretera de Colmenar Viejo, Km 9, 100, 28034 Madrid, Spain *Corresponding author. E-mail address: sdlazlobato@gmail.com (S. Diaz-Lobato).
21 July 2015 22 October 2015 http://dx.doi.org/10.1378/jrppnen.2015.10.008 2173-5115/ © 2015 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
in 1959, and the American Thoracic Society Symposium, in 1962, there was much confusion regarding the diagnosis of chronic bronchitis and emphysema, and the concept of airflow obstruction was only introduced at that time.11 Gradually, doctors and scientists concern with the pathology and the clinic moved toward the pathophysiology, giving rise to the actual concept of COPD.

Cigarette mass production began circa 1880, and their consumption has increased until now, but the association with COPD was only established once the latent effects of cigarettes became apparent, in the second half of the 20th century. With the progressive increase of smoking, initially solely in the developed countries, an easier access to the quantification of exposure, and a well-documented association to COPD, tobacco smoking became the most important risk factor for COPD. But COPD, even under the old label of emphysema or chronic bronchitis, was probably very common before tobacco smoking was widespread, although little recognized.

In 1846 Hutchinson invented the spirometer, so important to the diagnosis of COPD, but only recently the industry and technology made possible the emergence of handheld spirometers, accurate and inexpensive, and their spread in the primary care medicine, although there is a lack of accessibility in our country, as suggested by the BOLD study in Lisbon.5 FEV1/FVC, more than defining obstruction, is a sensitive test for early stages of airflow limitation, and, when <70%, heralds the onset of rapid decline in FEV1. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was initiated in 1998, and the first report issued in 2001.12 Rather than a new disease, the generalization of these two tools, the spirometer and the GOLD consensus report, enabled showing COPD as a common disease and a leading cause of morbidity and mortality worldwide, giving to COPD importance and visibility.

However, the term COPD is more than a new label for an old disease: is a new concept, as proposed by the GOLD working definition; is chronic and common; is preventable and treatable; is a complex disease based on inflammation, its pathological hallmark; is a heterogeneous disorder, and also heterogeneous in its presentation. And exacerbations and comorbidities contribute to the overall severity. Any individual patient may have emphysema, or peripheral airways disease, or chronic bronchitis, or all of these conditions,13 but the dominant clinical feature is persistent and usually progressive airflow limitation, that is the hallmark of COPD.

Conflicts of interest
The author has no conflicts of interest to declare.

References

A. Araújo
Respiratory Department, H. St. Oliveira, Guimarães, Portugal
E-mail address: duartearaujodr@sapo.pt

http://dx.doi.org/10.1016/j.rppn.2016.02.008
2173-5115/
© 2016 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).